Literature DB >> 9523848

Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury.

C Biron1, H Andréani, P Blanc, J Ramos, J Ducos, N Guigue, H Michel, D Larrey, J F Schved.   

Abstract

Antiphospholipid antibodies (APAs) have been reported in various clinical conditions. However, the pathogenesis and clinical significance of these antibodies are still unclear. The objective of this study was to assess the prevalence of APAs in patients with chronic alcohol- or hepatitis C virus (HCV)-related liver disease and to evaluate their relation to the underlying liver disease. We prospectively studied 201 patients referred to an hepato-gastroenterology department, including 77 patients with a history of alcohol abuse (group I) and 124 with chronic HCV infection (group II), and 107 healthy subjects (control population). Liver biopsy was performed in all patients. In cirrhotic patients, the severity of the liver disease was assessed with the use of Child's classification, as modified by Pugh. Several biologic parameters, including lupus anticoagulant and anticardiolipin antibodies, were determined. Forty-eight percent of patients in group I and 33% of those in group II had APAs. Among cirrhotic patients, APAs were more frequent in patients with Child grade B or C than in those with grade A severity. In patients with chronic HCV-related liver disease, a correlation was found between APA levels and liver fibrosis (P = 0.009); no relation was found between APA levels and histologic liver disease activity (P = 0.25). In the control group, one subject was APA-positive. None had lupus anticoagulant. APAs seem to be frequently associated with chronic liver disease of various causes. These results suggest further investigations on the potential role of these antibodies in fibrosis or liver injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523848     DOI: 10.1016/s0022-2143(98)90096-8

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome.

Authors:  J Ordi-Ros; J Villarreal; F Monegal; S Sauleda; I Esteban; M Vilardell
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections.

Authors:  H Guglielmone; S Vitozzi; O Elbarcha; E Fernandez
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 3.  The antiphospholipid syndrome and infection.

Authors:  G N Dalekos; K Zachou; C Liaskos
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

4.  Antiphospholipid antibodies in HIV-positive patients.

Authors:  Liliana Galrão; Carlos Brites; Maria Luíza Atta; Ajax Atta; Isabella Lima; Fernanda Gonzalez; Fernanda Magalhães; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2007-02-28       Impact factor: 2.980

5.  Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids.

Authors:  R Rolla; D Vay; E Mottaran; M Parodi; M Vidali; M Sartori; C Rigamonti; G Bellomo; E Albano
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

Review 6.  Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

Authors:  Emilio González-Reimers; Geraldine Quintero-Platt; Candelaria Martín-González; Onán Pérez-Hernández; Lucía Romero-Acevedo; Francisco Santolaria-Fernández
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

Review 7.  Thrombosis Associated with Viral Hepatitis.

Authors:  Luca Galli; Victor E A Gerdes; Luigina Guasti; Alessandro Squizzato
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

Review 8.  Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis.

Authors:  Xingshun Qi; Valerio De Stefano; Chunping Su; Ming Bai; Xiaozhong Guo; Daiming Fan
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

Review 9.  Unusual manifestations of the antiphospholipid syndrome.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.